Project Grant R01HL169297
Award Date
9/6/24
Completion Date
6/30/28
Dollars Obligated
$1.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This R01 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $596,179 over a 5-year period beginning on January 1, 2025 to conduct research on the role of macropinocytosis, a cellular process, in the development of pulmonary fibrosis. The research aims to determine whether inhibiting macropinocytosis can attenuate fibrosis in animal models and cell culture systems, as well as elucidate the molecular mechanisms by...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the VPS34 protein in the development and progression of pulmonary arterial hypertension (PAH). The $491,056.01 award, effective May 20, 2025 through April 30, 2028, aims to examine the regulation and function of VPS34 in PAH, determine its impact on proliferation and survival of pulmonary artery...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $522,794 to the University of Illinois to conduct research on the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The project aims to use transgenic mice and in vivo approaches to delineate HV1's contributions to pulmonary hypertension pathogenesis, examine the molecular mechanisms, and...
This $1,546,880 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the regulatory mechanisms governing myofibroblast differentiation in idiopathic pulmonary fibrosis (IPF). The primary objectives are to: 1) determine the "regulatory architecture" of open chromatin in myofibroblasts in IPF, 2) examine how expression levels of E-box transcription factors...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $812,189 to Brigham & Women's Hospital Inc. for a research project titled "Clinical CT Imaging for Screening and Subtyping of Pulmonary Hypertension in COPD". The project aims to leverage CT imaging data from several NIH-funded cohorts, including PVDOMICS, COPDGENE, and CARDIA, to develop non-invasive methods for diagnosing...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from September 15, 2024 to June 30, 2026. The goal of this project is to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $740,317 to The Washington University in St. Louis to conduct research on the regulation of alveologenesis, the final phase of lung development, by FGF signaling pathways. The research aims to identify the cellular mechanisms by which FGF signaling regulates cell proliferation, differentiation, and death during the first and second stages...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $596,809 to Emory University to conduct research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The research aims to elucidate how MitoNEET regulates pulmonary artery smooth muscle cell function and mitochondrial bioenergetics, and to evaluate the potential of MitoNEET ligands as novel therapies for group 3 PH,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research focused on reversing pathogenic remodeling in idiopathic pulmonary fibrosis (IPF). The key objectives are to define pro-reparative differentiation pathways in the fibroblast and stem cell compartments that can be leveraged as therapy, and...